Strontium Modified Calcium Sulfate Hemihydrate Scaffold Incorporating Ginsenoside Rg1/Gelatin Microspheres for Bone Regeneration

Peng Luo1,2†, Lan Yu3†, Qiang Lin4, Changde Wang5, Dazhi Yang1,2* and Shuo Tang6*

1 Department of Orthopaedics, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China, 2 Department of Orthopaedics, The 6th Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen, China, 3 Department of Laboratory, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China, 4 Department of Orthopaedics, Guangdong Hospital of Traditional Chinese Medicine, Guangzhou, China, 5 Department of Geriatric Orthopaedics, Shenzhen Pingle Orthopaedic Hospital, Shenzhen, China, 6 Department of Orthopaedics, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China

The aim of this study was to prepare a promising biomaterial for bone tissue repair and regeneration. The Strontium – calcium sulfate hemihydrate (Sr-α-CaS) scaffold incorporating gelatin microspheres (GMs) encapsulated with Ginsenoside Rg1 (Rg1) was designed. The scaffolds of Rg1/GMs/Sr-α-CaS showed sustained release of Rg1, good biocompatibility and ability of promoting osteogenic differentiation and angiogenesis in vitro. The scaffolds were implanted into animal model of cranial bone defect to characterize bone tissue repair and regeneration in vivo. From the images of Micro-CT, it was obvious that the most bone tissue was formed in Rg1/GMs/Sr-α-CaS group in 12 weeks. New bone structure, collagen and mineralization were analyzed with staining of HE, Masson and Safranin O-Fast green and showed good distribution. The expression of osteocalcin of Rg1/GMs/Sr-α-CaS indicated new bone formation in defect site. The results revealed that synergy of Rg1 and Sr showed the best effect of bone repair and regeneration, which provided a new candidate for bone defect repair in clinic.

Keywords: Ginsenoside Rg1 (Rg1), gelatin microspheres, strontium (Sr), calcium sulfate hemihydrate (α-CaS), bone defect

INTRODUCTION

Large bone defect caused by trauma and tumor resection is still a severe problem in clinic for the limited self-repair capability and absence of transplant. Tissue engineering provides a feasible method for bone repair and regeneration (Porter et al., 2009). Compatible mechanical strength and good biocompatibility are especially important for ideal substitute of bone tissue. Inorganic biomaterials of hydroxyapatite, β-Tricalcium phosphate, and calcium sulfate has been reported widely (Gotterbarm et al., 2014; Ramesh et al., 2018; Meng et al., 2019). Calcium sulfate has been used as a bone defect filling and repairing material for over a 100 years. It has good biocompatibility and can be degraded and absorbed into the body without immune reaction (Kutkut and Andreana, 2010). Commercial medical calcium sulfate products such as Osteoset (Wright, United States) are used into clinic, which change CaSO4·H2O into CaSO4·0.5H2O and can be degraded within 6–8 weeks in vivo (Winn and Hollinger, 2000). α-CaSO4·0.5H2O loading bone morphogenetic proteins-2 (BMP-2) peptide was reported to repair a critical defect in the femoral condyle of rabbit (Liu et al., 2015b). The rapid solidification of α-CaSO4·0.5H2O make it a candidate as...
bone. \(\alpha\text{-CaSO}_4\cdot 0.5\text{H}_2\text{O}\) was mixed with bioactive glasses and the mixture had potential used as the substitute of bone implant (Zheng et al., 2018b).

Strontium (Sr) is an alkaline earth metal element and plays an important physiological function in human body. Strontium ranelate is used to treat severe osteoporosis in postmenopausal women authorized by the European Union (Barenholdt et al., 2009). Sr is also used widely in bone tissue engineering. Sr can substitute Calcium (Ca) for their similar ion diameter, and when the concentration of Sr > 0.2 mol L\(^{-1}\), it would induce partial conversion of Calcium sulfate dihydrate to hemihydrate (Feldmann and George, 2013). Sr also has bone-seeking properties, and it can replace Ca to strength mechanical behaviors (Jimenez et al., 2019). The cement of Sr-containing \(\alpha\)-calcium sulfate hemihydrate was reported with enhanced osteobiological differentiation, new bone and new blood vessel formation in critical-sized calvarial defects \textit{in vivo} (Yang et al., 2017). In our previous study, Sr substituted hydroxyapatite/silk fibroin scaffold loading BMP-2 increased bone mineral density (BMD) and improved new bone regeneration (Yang et al., 2017). For mesenchymal stem cells (MSCs), it was found that Sr activated Wnt/Catenin signaling to promote osteogenic differentiation \textit{in vitro} (Yang et al., 2018). For osteonecrosis \textit{in vivo} and \textit{in vitro} (Yang et al., 2011). Sr also enhanced osteoblast activity and inhibited osteoclast activity (Wornham et al., 2014).

Ginsenoside Rg1 extracted from dry root of Panax ginseng C. A. Mey has many physiological functions for the antioxidant and anti-inflammatory properties (Gao et al., 2017b; Ghaemini et al., 2018). For bone repair and regeneration, Rg1 was demonstrated to have protective effects on BMSCs apoptosis by activating mir-494-3p. ROCK-1. Bcl-2 signaling pathway in male rat (Zheng et al., 2018a). Rg1 was also reported to promote osteogenic differentiation with activated GR/BMP-2 signaling pathway \textit{in vitro} and \textit{in vivo} (Yang et al., 2011). Sr also enhanced osteoblast activity and inhibited osteoclast activity (Wornham et al., 2014).

Ginsenoside Rg1 extracted from dry root of Panax ginseng C. A. Mey has many physiological functions for the antioxidant and anti-inflammatory properties (Gao et al., 2017b; Ghaemini et al., 2018). For bone repair and regeneration, Rg1 was demonstrated to have protective effects on BMSCs apoptosis by activating mir-494-3p. ROCK-1. Bcl-2 signaling pathway in male rat (Zheng et al., 2018a). Rg1 was also reported to promote osteogenic differentiation with activated GR/BMP-2 signaling pathway \textit{in vitro} and \textit{in vivo} (Yang et al., 2011). Sr also enhanced osteoblast activity and inhibited osteoclast activity (Wornham et al., 2014).

Ginsenoside Rg1 (>98%, Aladdin, China); Gelatin (Porcine skin, Type A, Sigma-Aldrich, United States); Span 80 (Aladdin, China); Olive oil (Aladdin, China); SrCl\(_2\)-6H\(_2\)O (Aladdin, China); Gibco MEM \(\alpha\), Nucleosides (Thermo Fisher Scientific, United States); Fetal bovine serum (FBS, Sigma-Aldrich, United States); Anti-Osteocalcin (Anti-OCN, Santa Cruz Biotechnology, United States); CCK-8 Kit (Beyotime, China); ALP Kit (Beyotime, China); RNAsay Mini Kit (Qiagen, United States); cDNA synthesis Kit (Beyotime, China); Bulge-LoopTM miRNA qRT-PCR kit (Ribobio, Guangzhou, China); Hematoxylin and Eosin Staining Kit (Beyotime, China); Masson’s Trichrome Stain Kit (Mkbio, Shanghai, China); and Safranin O-Fast green Stain Kit (Servicebio, Wuhan, China).

**Cell Culture**

MC3T3-E1 cells (Biowit Biotech, Shenzhen, China) were cultured in MEM\(\alpha\) culture medium supplemented with 10% FBS and 1% Penicillin-Streptomycin at 37°C, 5% CO\(_2\) humidified atmosphere. The medium was changed every 2 days for further experiment.

**Preparation of Rg1 Loaded Gelatin Microspheres (Rg1/GMs)**

Gelatin microspheres (GMSs) were prepared with an emulsion solvent evaporation method with a slight modification (Yang et al., 2009). 0.1 g sorbitol oleate (Span-80) was added to 100 mL olive oil, heating in a water bath at 60°C for 0.5 h at 400 rpm. After mixing evenly, add 10 mL gelatin solution of 10 wt% drop by drop. After stirring for 3 h, transfer the mixed solution to the ice bath and keep the rotation speed for 30 min. Then, 0.1 mL of 25 wt% aqueous solution of glutaraldehyde was added. After 2 h stirring, add 30 mL acetone at 4°C and stir for 30 min. The product was placed into 10 mL acetone for further curing for about 24 h at 4°C. Then, the microspheres were gained and soaked into 1 mol/L aminoacetic acid for 30 min and washed alternately by ethanol and isopropyl alcohol for three times. Finally, freeze-drying to obtain GMSs. Rg1/GMs were prepared similarly. 10 mg Rg1 was dispersed into 10 mL gelatin solution of 10 wt%. Then, the mixture was added in olive oil with Span-80, and repeat the methods as above. Rg1 was loaded into GMSs to form Rg1/GMs. The microspheres with different mass ratio of Rg1 and GMs were prepared, and cell proliferation of MC3T3-E1 was used to evaluate the best dosage of Rg1.

**Preparation of Rg1/GMs/Sr-\(\alpha\)-CaS Scaffold**

\(\alpha\text{-CaSO}_4\cdot 0.5\text{H}_2\text{O}\) (\(\alpha\text{-CaS}\)) calcium sulfate hemihydrate was synthesized first (Li et al., 2014). The composite crystalizer was prepared using sodium citrate, aluminum sulfate and sucinic acid with a mass ratio of 1:1:1. Solution of CaCl\(_2\) and K\(_2\)SO\(_4\) was evenly stirred with molar mass ratio of 1:1 in a sealed hydrothermal reaction vessel, and then adding composite crystallizer into vessel with dosage at 5% of the total mass of CaCl\(_2\) and K\(_2\)SO\(_4\). Dilute HCl was used to keep pH 5. Hydrothermal reaction was conducted for 4 h at 80°C, 300 r/min. The product was washed with hot water for three times and soaked in absolute ethanol to stop the reaction. After filtering, dry product in a vacuum oven for 4 h and at 105°C and get...
the final product of \( \alpha \)-CaS. \( \alpha \)-CaS was fully ground and sealed for next use. Sr-\( \alpha \)-CaS was prepared as above. SrCl\(_2\)·6H\(_2\)O and CaCl\(_2\) were dissolved and mixed with a molar ratio of 1:6. Then add K\(_2\)SO\(_4\) solution and keep the molar ratio at 1: 1 (m\( \text{Sr}^{2+} \& \text{Ca}^{2+} \): m\( \text{SO}_4^{2-} \)). Repeat the above steps to get Sr-\( \alpha \)-CaS. Rg1/GMs and Sr-\( \alpha \)-CaS were fully mixed up with a mass ratio of 1:100 by a planetary mixer (Nova, Shanghai, China) at 50–200 r/min. The homogeneous powder was pressed into a sheet-like scaffold with a tableting machine (Lvyi, Shanghai, China) under 10–20 MPa.

**Characterization of Rg1/GMs/Sr-\( \alpha \)-CaS Scaffold**

Morphology of gelatin microspheres was measured by scanning electron microscope (SEM, Philips XL-30; Philips, Netherlands). Crystal structure of \( \alpha \)-CaS and Sr-\( \alpha \)-CaS was tested by X-ray diffractometer (XRD, Gemini S Ultra, Oxford Diffraction Ltd., Japan). The infrared (IR) spectra were obtained by Fourier transform infrared spectroscope (FTIR, VERTEX70, Bruker, Germany). The size and shape of \( \alpha \)-CaS were determined.
by Transmission electron microscopy (TEM, Philips Tecnai-10; Philips, Netherlands) and quantitative analysis of elements was performed by Energy Dispersive Spectrometer (TEM-EDS). Composition was detected by Thermogravimetric analyzer (TG, TG 209; NETZSCH, Germany).

**Loading Rate and Release of Rg1 in vitro**
The quantification of Rg1 was detected by High performance liquid chromatography (HPLC, UltiMate 3000; Thermo Fisher Scientific, United States). The mobile phase was composed with acetonitrile (mobile phase) and 0.05% Na$_2$HPO$_4$ (PB, pH: 7, mobile phase B). The detection wavelength was selected at 203 nm. The standard Rg1 solution of 1 mg/mL was prepared and diluted into different concentrations. The HPLC assay was processed. Draw the standard curve of Rg1 and calculate the loading rate of Rg1/GMs. Scaffolds of Rg1/Sr-α-CaS and Rg1/GMs/Sr-α-CaS and 10 mg microspheres of Rg1/GMs were soaked into 10 mL PBS with pH 7.4 at 37°C. At the set time, 0.5 mL supernatant was collected and replaced by 0.5 mL fresh PBS. The collected supernatant was stored at –20°C. After all the samples were collected, the HPLC assay was carry out at 203 nm as above. The cumulative release of Rg1 was calculated via standard curve line. All experiments repeated in triplicate for each time interval and draw the cumulative release curve.

**Cytotoxicity Assay in vitro**
Leaching solution of each scaffold of Sr-α-CaS, Rg1/Sr-α-CaS and Rg1/GMs/Sr-α-CaS was prepared according to international standard. In brief, scaffolds were soaked into ethanol of 75% and conducted UV radiation for 30 min, respectively. Then, wash scaffolds with PBS for 2–3 times. Add medium with ten times the mass of scaffolds and incubate for 24 h at 37°C. MC3T3-E1 cells in logarithmic growth phase were digested and adjusted to $5 \times 10^4$ cells/mL. 100 µL cell suspension was added to 96-well plates. After growth for 24 h, replace the medium with leaching solution and continue to culture cells for 1, 4, 7, and 10 days. CCK-8 Kit was used to evaluate cell viability. Add CCK-8 reagent with a volume ratio of 1:9 ($V_{\text{medium}}: V_{\text{CCK-8}} = 1:9$) and incubate
Luo et al. (Sr-α-CaS) Scaffold for Bone Regeneration

FIGURE 4 | Micro-CT images (A) of different scaffolds in rat calvarial defects; Micro-CT analysis of BT/TV (B) and BMD (C) in the rat calvarial defects. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

for 30 min according to manufacturer’s instruction. Test the absorbance wavelength at 450 nm of each well using a microplate reader (MM-58938-00, Molecular Devices, United States) and calculate the cell viability.

Alkaline Phosphatase (ALP) in vitro
The osteogenic differentiation of MC3T3-E1 was evaluated with ALP activity test, which was a distinct feature of osteoblast differentiation. MC3T3-E1 cells were digested and adjusted to 3 × 10^4/mL, and 500 µL cell suspension was adding to 24-well plates. After incubating for 24 h, replace medium with 500 µL leaching solution. While culturing for 1, 7, 14, and 21 days, wash cells with PBS for three times and add 500 µL cell lysates. Cells were disrupted using an ultrasonic cell disrupter (Fisher Scientific 50, Thermo Fisher Scientific, United States) at 4°C. Centrifugate and collect supernatants, add 500 µL ALP substrate reaction solution. The reaction was carried out for 30 min at 37°C, 500 µL of 0.1 M NaOH was added to terminate the reaction. The UV absorption at 405 nm was then determined using ultraviolet-visible spectrophotometer (UV-2550, Shimadzu, Japan). ALP activity was calculated according to instructions. Each group of scaffolds at each time point was tested at least three times in parallel.

VEGF Expression in vitro
MC3T3-E1 cells were cultured with leaching solution in 24-well plates as above for 1, 4, 7, and 21 days. The cells were collected and total RNA was extracted with RNeasy Mini Kit.
Reverse transcription of total RNA to obtain cDNA according to manufacture instruction. cDNAs and equal amounts of forward and reverse primers were added into a SYBR reaction mixture. The qPCR conditions were 2 min at 50°C, 10 min at 95°C, 50 cycles at 95°C for 15 s, and 1 min at 60°C. miRNA qRT-PCR was detected by the Bulge-LoopTM miRNA qRT-PCR kit. VEGF forward primers: 5'-ACAGGAAGGAGCACAGAAGCCCAT-3'; Reverse primer: 5'-CGCTCTGACCAAGGCTCACAGT-3'; GAP DH forward primer: 5'-AGGTCGGTGTCACACGGATTT and reverse primer: 3'-CCTTCCACGATGCCAAAGTT.

Animal Model of Cranial Bone Defect
All animal experiments were strictly carried out in accordance with the regulations of the Animal Research Center of Sun Yat-sen University. 18 SD rats (200–250 g) were divided into three groups (n = 6): Sr-α-CaS, Rg1/Sr-α-CaS and Rg1/GMs/Sr-α-CaS. The scaffold (diameter: 8 mm, weight: 183.3 mg) implantation into calvarial defect was shown in Supplementary Figure S5. Before the operation, sodium pentobarbital solution of 1% was intraperitoneally injected into SD rats at a dose of 30 mg/kg. Remove the hair of the rat brain, and cut a 3 cm long scalp in the middle of the rat's head. At the same time, the subcutaneous tissue on both sides was peeled off. After removing the periosteum, a calvarial defect model with a diameter of 6 mm was constructed using a dental drill in the middle of the rat’s parietal bone. Take care during the operation to maintain the integrity of the dura mater. The sterilized scaffolds were sequentially implanted into the calvarial defects as shown in Supplementary Figure S5C, and the periosteum and scalp were sutured (Supplementary Figure S5D). After 4, 8, and 12 weeks of implantation, the rats were sacrificed and the skulls were dissected and placed in a 4% paraformaldehyde solution for subsequent histological characterization.

Micro-CT in vivo
After 4, 8, and 12 weeks postoperatively, the rats were anesthetized, and then the defect was analyzed using the Micro-CT imaging system (BRUKER Micro-CT Sky Scan 1176, Bruker, United States). The parameters of the device were set: the layer thickness: 48 µm; the spacing between the layers: 48 µm; the pixel size: 48 µm and it was also set to high voltage mode. The bone volume and bone density of regenerated bone tissue were calculated using the software provided by Micro-CT.

Histological Analysis
After 4, 8, and 12 weeks, the removed samples were collected and soaked into 4% solution of paraformaldehyde at room temperature for 24 h. Subsequently, the fixed samples were immersed in 10% EDTA solution for decalcification of about 45 days, and the decalcification solution was changed every 3 days until the bone tissue needle can pass smoothly. Then, different concentrations of ethanol solution were used for dehydration. The samples were subjected to lateral paraffin embedding, and sliced vertically with 5 µm thickness. Finally, staining of hematoxylin-eosin (H&E), Masson's trichrome and Safranin/solid green were performed to characterize the bone tissue repair and regeneration.

Immunohistochemistry
Osteocalcin was a protein formed by osteoblasts to constitute new bone. The antibody of anti-OCN was used to evaluate
FIGURE 6 | Masson staining of Sr-α-CaS, Rg1/Sr-α-CaS and Rg1/GMs/Sr-α-CaS (Magnification = 100×, black arrow: collagen fibers).

the regeneration of bone tissue. The samples were prepared into sections as above. Sections were incubated with anti-OCN primary antibody (1: 200) overnight at 4°C. Then, add a secondary antibody (1: 500) to incubate for 2 h at room temperature. Diaminobenzidine (DAB) coloring agent was to perform protein distribution and observe OCN expression with light microscope (Olympus IX71, Japan).

Statistical Analysis
The data of this study were averaged ± standard deviation (SD) of statistical data using SPSS software (version 16.0; SPSS, Chicago, IL, United States). At least three parallel samples (n = 3) were set for all experiments. * indicates \( p < 0.05 \), ** indicates \( p < 0.01 \), and the smaller the \( p \)-value, the more the corresponding * is, the difference of \( p < 0.05 \) is considered to be statistically significant.

RESULTS

Characteristics of Scaffolds
The XRD diffraction patterns were shown in Figure 1A, the diffraction peaks of \( \alpha \)-CaS at 15.1° (200), 26.2° (020), 30.5° (400), 32.6° (204), 43.0° (422), 50.1° (424), and 54.8° (604) were consistent with standard \( \alpha \)-CaSO_4·0.5H_2O (PDF#41-0224). Sr-\( \alpha \)-CaS had similar characteristic peaks with \( \alpha \)-CaS, and diffraction peaks of Sr\(^{2+}\) presented at 27.5° and 28.5° (Li et al., 2014). FTIR spectrum of \( \alpha \)-CaS was in Figure 1B. Characteristic absorption peaks at 1150, 660, and 605 cm\(^{-1}\) presented asymmetric stretching vibration and bending vibration of SO_4\(^{2-}\) and characteristic peak at 3613 cm\(^{-1}\) was vibration of O-H. The results of XRD and FTIR of \( \alpha \)-CaS indicated \( \alpha \)-CaSO_4·0.5H_2O was successfully synthesized, and with the incorporation of Sr, the crystal structure of \( \alpha \)-CaS was not significantly affected. TEM images was showed in Figures 1C,D. Whisker of \( \alpha \)-CaS can be observed while Sr-\( \alpha \)-CaS appeared larger particle and size thicker rod, which may be caused by the different growth rate of Sr\(^{2+}\) in the length direction and diameter direction of whisker surface. Elemental analysis from EDS in Figures 1E,F and Table 1 showed the content of Sr was 16.1%. The composition of Sr-\( \alpha \)-CaS was also tested by TG in Figure 2A. As temperature rise, both mass of \( \alpha \)-CaS and Sr-\( \alpha \)-CaS declined, and content of Sr was about 8.7%. Calcium sulfate hemihydrate containing 16.1% Sr (Sr-\( \alpha \)-CaS) was prepared successfully. The SEM of gelatin microspheres was in Supplementary Figure S1, and the average diameter was 9.24 ± 0.87 \( \mu \)m, surface area was 268.09 ± 50.48 \( \mu \)m\(^2\). The average diameter of pores in microspheres was also measured, which was 0.59 ± 0.06 \( \mu \)m. The SEM images of scaffolds were in Supplementary Figure S2. Compared with Sr-\( \alpha \)-CaS, Rg1/GMs/Sr-\( \alpha \)-CaS scaffolds showed rougher surface and round gelatin microspheres can be observed. Cell proliferation of MC3T3-E1 cells cultured with different ratio of Rg1/GMs was shown in Supplementary Figure S3. While Rg1/GMs ratio was 10:1, the highest proliferation rate can be obtained.

Loading Rate and Release of Rg1 in vitro
The standard curve of Rg1 was in Supplementary Figure S4, regression equation was \( Y = 0.00426X - 0.0002835, R^2 = 0.9993 \), linear range was 3.125–50.000 mg/L, which showed good correlation in the linear range. The loading rate of Rg1/GMs was obtained by calculating the peak area in chromatograms, and it was 2.51% (w/w). Cumulative release curve of Rg1 was in Figure 2B, which was calculated using the standard
Luo et al. (Sr-α-CaS) Scaffold for Bone Regeneration

FIGURE 7 | Safranin O and Fast Green staining photomicrographs of calvarial defect sites treated with Sr-α-CaS, Gim/Sr-α-CaS and Gim/GMS/Sr-α-CaS (Magnification = 100×, black arrow: bone tissue).

TABLE 1 | The element weight of different α-CaS and Sr-α-CaS.

|          | C  | O  | S  | Sr | Ca | Sr/(Sr+Ca) |
|----------|----|----|----|----|----|------------|
| α-CaS    | 49.29 | 21.12 | 13.80 | 0  | 15.79 | 0          |
| 10% Sr-α-CaS | 30.82 | 24.26 | 20.38 | 16.1 | 22.93 | 6.56       |

In first 36 h, Rg1 was almost completely released from Rg1/Sr-α-CaS. However, for Rg1/GMs and Rg1/GMs/Sr-α-CaS, release rate decreased significantly and Rg1 showed sustained release without drug burst. Compared with Rg1/GMs, release rate of Rg1/GMs/Sr-α-CaS was always slower, and cumulative release of Rg1/GMs was 92% while it was 85% in Rg1/GMs/Sr-α-CaS within 120 h. Although the scaffolds of Sr-α-CaS had good degradability, GMs can be used as drug carriers to maintain sustained release of Rg1, which caused the above results. It demonstrated that Rg1/GMs/Sr-α-CaS can provide Rg1 stably to repair bone defect in vivo.

Cytotoxicity in vitro

To evaluate biocompatibility of scaffolds, cytotoxicity was conducted and 0.5wt% phenol was used as negative group. After culturing MC3T3-E1 cells for 1, 4, 7, and 10 days with leaching solution, cell viability was measured by CCK-8 assay in Figure 2C. Compared with control group, all the scaffolds showed good biocompatibility, and cell viability was more than 90%. The results demonstrated Sr-α-CaS was safe and incorporation of Sr did not affect the biocompatibility of scaffolds. What's more, Rg1/GMs/Sr-α-CaS showed the highest cell viability and it may be caused by slight release of Rg1.

ALP in vitro

The expression of ALP in Figure 3A indicated the osteogenic differentiation of MC3T3-E1. After culturing for 1, 7, 14, and 21 days, ALP activity gradually increased with time, and all scaffolds presented higher ALP activity than control group, which indicated each scaffold can provide support for osteogenic differentiation of MC3T3-E1. Scaffolds with Sr and Rg1 showed higher ALP expression in 14 and 21 days. Therefore, synergistic effect of Rg1 and Sr prompted osteogenic differentiation. However, compared with Rg1/Sr-α-CaS group, ALP activity of Rg1/GMs/Sr-α-CaS showed significant increase at 14 and 21 days. Due to sustained release of Rg1 from GMs, concentration of Rg1 in leaching solution of Rg1/Sr-α-CaS was higher than Rg1/GMs/Sr-α-CaS group, which was consistent with the result of cumulative release curve. Therefore, it was inferred that low concentration of Rg1 was more conducive to osteogenic differentiation.

VEGF Expression in vitro

VEGF expression was related to blood vessel formation, and it was measured by RT-qPCR at 1, 7, 14, and 21 days. In Figure 3B, all the scaffold groups showed significant increase in VEGF expression. Scaffolds with Sr and Rg1 also showed higher expression of VEGF than other group in 14 and 21 days. But compared with Rg1/Sr-α-CaS, VEGF expression of Rg1/GMs/Sr-α-CaS was increased obviously, which was consistent with results of ALP expression. It was also inferred that low concentration of Rg1 can effectively promote vasculization.
Micro-CT

Scaffolds of Sr-α-CaS, Rg1/Sr-α-CaS, and Rg1/GMs/Sr-α-CaS were implanted into skull defect. The repair and regeneration in defect site were evaluated by Micro-CT in Figure 4A. It was obvious that more bone tissue was observed in scaffolds with Sr and Rg1 for 12 weeks. Compared with Rg1/Sr-α-CaS group, more bone tissue was formed in Rg1/GMs/Sr-α-CaS group for 8 weeks, thus sustained Rg1 and Sr appeared the highest efficiency of cranial bone repair. New bone volume and BMD was calculated in Figures 4B,C. The volume of new bone increased with time for each scaffold, and Rg1/GMs/Sr-α-CaS group always showed the most bone volume. At 12 week, the BV/TV of Rg1/GMs/Sr-α-CaS rise up to 83% while it was only 78% in Rg1/Sr-α-CaS and 69% in Sr-α-CaS. BMD also increased with time. Scaffolds with Rg1 showed higher BMD than Sr-α-CaS, and Rg1/GMs/Sr-α-CaS group always had the highest BMD in vivo. It revealed that Rg1 and Sr promoted new bone formation with enhanced bone volume and BMD.

Histology

HE staining of bone tissues in defect site for 4, 8, and 12 weeks was exhibited in Figure 5. After 4 week of implantation, no obvious inflammatory response was found in all groups and a small amount of bone trabecula (black arrows) was observed in Rg1/GMs/Sr-α-CaS group. After 8 week, bone trabecula and fibrous tissue in defect site were found. For 12 week, the trabecular bone became thicker and a large number of new bone formation was observed in all groups, and the morphology of newborn bone tissue (black rectangle) in Rg1/GMs/Sr-α-CaS was similar with normal tissue.

Immunohistochemistry

Osteocalcin, a structural protein from osteoblast, played an important role in regulating bone calcium metabolism and was processed to produce carboxylate osteocalcin to participate bone development. In Figure 8 and Supplementary Figure S6A, every scaffold showed low expression of OCN at 4 week. Rg1 loaded scaffolds showed higher OCN expression (black arrows) at 8 weeks, which was more obvious at 12 weeks. Therefore, sustained release of Rg1 accelerated bone regeneration in vivo.
DISCUSSION

Biomaterials of Sr modified calcium sulfate hemihydrate have been reported in bone repair. The scaffold of Sr-CaS showed good biocompatibility and repair in tibia bone defect of SD rats, which activated TGF-β/Smad signaling pathway to improve bone formation (Liu et al., 2019). Traditional Chinese medicine recently has become a hot research topic in life sciences. As a precious medicine, Panax ginseng C. A. has always been regarded as the king of herbs. Ginsenosides are considered to be active ingredients in ginseng (Lee and Kim, 2014; Biswas et al., 2017; Mohanan et al., 2018). The dose of Ginsenosides Rg1 was reported to have influence on cell growth and tissue differentiation such as adipose-derived stromal cells (ASCs) (Liang et al., 2019), neural stem cells (Li et al., 2015; Gao et al., 2017a), and human dental pulp cells (hDPCs) (Wang et al., 2012). For the cartilage repair and regeneration, the dosage of Rg1 was related to cell proliferation and chondrogenic differentiation of breast adipose-derived stem cells HBASCs (Xu et al., 2015). The dose-effect of Rg1 was also found in human periodontal ligament stem cells (hPDLSCs), and concentration from 10 to 100 µmol/L was investigated. Rg1 at 10 µmol/L significantly enhanced the proliferation and osteogenic differentiation of hPDLSCs while 100 µmol/L Rg1 caused cytotoxicity (Yin et al., 2015).

In this study, we firstly introduced Rg1 to Sr-α-CaS scaffold, and both of Rg1 and Sr accelerated repair and regeneration of cranial bone. To avoid drug burst release, Rg1 was loaded to gelatin microspheres. From the results of Micro-CT in Rg1/GMs/Sr-α-CaS group, the new bone volume was about 83.3% in 12 weeks and BMD increased to 1133 mg/cm³. Scaffolds also need to provide mechanical support and the mechanical properties should be as close as possible to normal tissue. As we knew, single calcium sulfate hemihydrate scaffolds were absorbed and metabolized too quickly for its rapid degradation. With the incorporation of Sr and Rg1/GMs, mechanical properties were improved and the Rg1 release was prolonged, which made scaffold of Rg1/GMs/Sr-α-CaS a promising candidate for bone repair. The main components of natural bone are hydroxyapatite and collagen. In order to match the degradation rate and mechanical properties with the natural bone, we are considering to prepare composite scaffolds with cross-linked natural biomaterials. To mimic the structure and function of natural bone tissue, natural biomaterials such as collagen, silk fibroin, and chitosan have been reported to add to calcium sulfate hemihydrate (Liu et al., 2015a, 2018; Chen et al., 2016).

Furthermore, dose of Rg1 also influenced the osteogenic differentiation and angiogenesis of MC3T3-E1 in vitro. In Figures 3A,B, Rg1/GMs/Sr-α-CaS group always showed higher expression of ALP and VEGF than Rg1/Sr-α-CaS. However, due to the degradation of scaffolds and sustained release of gelatin microspheres, the amount of Rg1 in leaching solution of Rg1/Sr-α-CaS was more than Rg1/GMs/Sr-α-CaS. The low concentration of Rg1 accelerated the osteogenic differentiation and vascularization of MC3T3-E1 in vitro while it was not obvious at high concentration. In future research, we would explore the effect of Rg1 concentration on cell proliferation and differentiation in vitro and tissue repair and regeneration in vivo.

In summary, this study prepared a novel Rg1/GMs/Sr-α-CaS scaffold to repair and regenerate cranial bone tissue. The scaffolds showed good biocompatibility and promoted osteogenic differentiation and vascularization in vitro and in vivo. The Rg1/GMs/Sr-α-CaS scaffolds combined traditional Chinese medicine with modern science and technology, and provided a possible way to study traditional herbs and a potential approach for bone repair and regeneration in clinic.

DATA AVAILABILITY STATEMENT

All datasets presented in this study are included in the article/Supplementary Material.

ETHICS STATEMENT

All experimental protocols were approved by the Ethics Committee in the Nanshan Hospital (protocol # 2018-C-106).

AUTHOR CONTRIBUTIONS

DY and ST designed the experiment. PL and QL completed the experiment and obtained the data. LY and CW also made substantial contributions to the experiment including the study design, in vitro and in vivo study, the acquisition, analysis, and interpretation of data for the work. All authors contributed to the article and approved the submitted version.

FUNDING

This study was supported financially by the Science and Technology Project of Shenzhen (Nos. JCYJ20190808102203649 and 20190802113709023), the Medical Science and Technology Foundation of Guangdong (No. A2020600), and the Science and Technology Project of Shenzhen Nanshan District (No. 2018050).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fbioe.2020.00888/full#supplementary-material

REFERENCES

Barenholdt, O., Kolthoff, N., and Nielsen, S. P. (2009). Reply to Letter Re: “Effect of long term treatment with strontium ranelate on bone strontium content” by Barenholdt et al. (Bone, 2009). Bone 45, 1026–1027. doi: 10.1016/j.bone.2009.07.003

Biswas, T., Mathur, A. K., and Mathur, A. (2017). A literature update elucidating production of Panax ginsenosides with a special focus on strategies enriching...
the anti-neoplastic minor ginsenosides in ginseng preparations. Appl. Microbiol. Biotechnol. 101, 4009–4032. doi: 10.1007/s00253-017-8279-4
Chen, Y. R., Zhou, Y. L., Yang, S. Y., Li, J. J., Li, X., and Ma, Y. F. (2016). Novel bone substitute composed of chitosan and strontium-doped alpha-calcium sulfate hemihydrate: Fabrication, characterisation and evaluation of biocompatibility. Mater. Sci. Eng. C-Mater. 66, 84–91. doi: 10.1016/j.msec.2016.04.070
Feldmann, T., and George, P. (2013). Demopoulos. influence of impurities on crystallization kinetics of calcium sulfate dihydrate and hemihydrate in strong HCl-CaCl2 solutions. Ind. Eng. Chem. Res. 52, 6540–6549. doi: 10.1021/ie302933v
Gao, J., Wan, F., Tian, M., Li, Y. Y., Li, Y. X., Li, Q., et al. (2017a). Si effects of ginsenoside-Rgl on the proliferation and glial-like directed differentiation of embryonic rat cortical neural stem cells in vitro. Mol. Med. Rep. 16, 8875–8881. doi: 10.3892/mmr.2017.7737
Gao, F., Chu, S. F., Zhang, Z., and Chen, N. H. (2017b). Hepatoprotective effects of ginsenoside Rg1-A review. J. Ethnopharmacol. 206, 178–183. doi: 10.1016/j.jep.2017.04.012
Ghaemnia, M., Rajkumar, R., Koh, H. L., Dawe, G. S., and Tan, C. H. (2018). Strontium-containing alpha-calcium sulfate hemihydrate promotes bone repair via the TGF-beta/Smad signaling pathway. Mol. Med. Rep. 20, 3555–3564.
Meng, Z. L., Wu, Z. Q., Shen, B. X., Li, H. B., Bian, Y. Y., Zeng, D. L., et al. (2019). Reconstruction of large segmental bone defects in rabbit using the Masquelet technique with alpha-calcium sulfate hemihydrate. J. Orthop. Surg. Res. 14:192.
Mohanan, P., Subramaniyan, S., Mathiyalagan, R., and Yang, D. C. (2018). Molecular signaling of ginsenoside Rb1, Rg1, and Rg3 and their mode of actions. J. Ginseng Res. 42, 123–132. doi: 10.1016/j.jgr.2017.01.008
Porter, J. R., Ruckh, T. T., and Popat, K. C. (2009). Bone tissue engineering: a review in bone biomimetics and drug delivery strategies. Biotechnol. Progr. 25, 1539–1560.
Ramesh, N., Moratti, S. C., and Dias, G. J. (2018). Hydroxyapatite-polymer biocomposites for bone regeneration: a review of current trends. J. Biomed. Mater. Res. B 106, 2046–2057. doi: 10.1002/jbm.b.33950
Wang, P., Wei, X., Zhou, Y., Wang, Y. P., Yang, Z., Zhang, F. J., et al. (2012). Effect of ginsenoside Rg1 on proliferation and differentiation of human dental pulp cells in vitro. Aust. Dent. J. 57, 157–165. doi: 10.1111/j.1834-7819.2012.01672.x
Winn, S. R., and Hollinger, J. O. (2000). An osteogenic cell culture system to evaluate the cytocompatibility of Osteoal, a calcium sulfate bone void filler. Biomaterials 21, 2413–2425. doi: 10.1016/0142-9612(00)00109-5
Wornham, D. P., Hajjawi, M. O., Orriss, I. R., and Arnett, T. R. (2014). Strontium potently inhibits mineralisation in bone-forming primary rat osteoblast cultures and reduces numbers of osteoclasts in mouse marrow cultures. Osteoporosis Int. 25, 2477–2484. doi: 10.1007/s00198-014-2791-5
Xu, F. T., Li, H. M., Zhao, C. Y., Liang, Z. J., Huang, M. H., Li, Q., et al. (2015). Characterization of chondrogenic gene expression and cartilage phenotype differentiation in human breast adipose-derived stem cells promoted by ginsenoside Rg1 in vitro. Cell Physiol. Biochem. 37, 1890–1902. doi: 10.1159/000438550
Yang, N. S., Feng, L. B., Zhu, Q. Y., Wang, W., Yan, L., Li, D., et al. (2018). Controlled release of BMP-2 from a heparin-conjugated strontium-substituted nanohydroxyapatite/silk fibrin scaffold for bone regeneration. Acs. Biomater. Sci. Eng. 4, 3291–3303. doi: 10.1021/acsbiomaterials.8b00459
Yang, F., Wu, S. G., Pan, Y. F., Song, F. L., and Li, T. (2009). Preparation and characteristics of erythromycin microspheres for lung targeting. Drug Dev. Ind. Pharm. 35, 639–645. doi: 10.1080/03639040802152243
Yang, F., Fang, D. Z., Tu, J., Zheng, Q. X., Cai, L. T., and Wang, L. P. (2011). Strontium enhances osteogenic differentiation of mesenchymal stem cells and in vivo bone formation by activating wnt/catenin signaling. Stem Cells 29, 981–991. doi: 10.1002/stem.646
Yang, S. Y., Wang, L., Feng, S. B., Yang, Q. M., Yu, B., and Tu, M. (2017). Enhanced bone formation by strontium modified calcium sulfate hemihydrate in ovariectomized rat critical-size calvarial defects. Biomed Mater. 12, 025004. doi: 10.1088/1748-6041/aa6b8c
Yin, L. H., Cheng, W. X., Qin, Z. S., Sun, K. M., Zhong, M., Wang, J. K., et al. (2015). Effects of ginsenoside Rg1 on the proliferation and osteogenic differentiation of human periodontal ligament stem cells. Chin. J. Integr. Med. 21, 667–681. doi: 10.1007/s11555-014-1856-9
Zheng, H. Z., Fu, X. K., Shang, J. L., Lu, R. X., Ou, Y. F., and Chen, C. L. (2018a). Ginsenoside Rgl protects rat bone marrow mesenchymal stem cells against ischemia induced apoptosis through miR-494-3p and ROCK-1. Eur. J. Pharmacol. 822, 154–167. doi: 10.1016/j.ejphar.2018.01.001
Zheng, Y. Y., Xiong, C. D., Zhang, D. J., and Zhang, L. F. (2018b). In vitro bioactivity evaluation of alpha-calcium sulphate hemihydrate and bioactive glass composites for their potential use in bone regeneration. B Mater. Sci. 41:59.

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Luo, Yu, Lin, Wang, Yang and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.